247 related articles for article (PubMed ID: 30795853)
41. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia.
Dinis-Ribeiro M; da Costa-Pereira A; Lopes C; Moreira-Dias L
J Gastroenterol Hepatol; 2007 Oct; 22(10):1594-604. PubMed ID: 17845687
[TBL] [Abstract][Full Text] [Related]
42. Role of Helicobacter pylori in gastric carcinoma.
Prabhu SR; Amrapurkar AD; Amrapurkar DN
Natl Med J India; 1995; 8(2):58-60. PubMed ID: 7735060
[TBL] [Abstract][Full Text] [Related]
43. Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia.
Ohkuma K; Okada M; Murayama H; Seo M; Maeda K; Kanda M; Okabe N
J Gastroenterol Hepatol; 2000 Oct; 15(10):1105-12. PubMed ID: 11106088
[TBL] [Abstract][Full Text] [Related]
44. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective.
Kapadia CR
J Clin Gastroenterol; 2003; 36(5 Suppl):S29-36; discussion S61-2. PubMed ID: 12702963
[TBL] [Abstract][Full Text] [Related]
45. Non-endoscopic diagnosis of multifocal atrophic gastritis; efficacy of serum gastrin-17, pepsinogens and Helicobacter pylori antibodies.
Hartleb M; Wandzel P; Waluga M; Matyszczyk B; Bołdys H; Romañczyk T
Acta Gastroenterol Belg; 2004; 67(4):320-6. PubMed ID: 15727075
[TBL] [Abstract][Full Text] [Related]
46. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years.
Hwang YJ; Kim N; Lee HS; Lee JB; Choi YJ; Yoon H; Shin CM; Park YS; Lee DH
Aliment Pharmacol Ther; 2018 Feb; 47(3):380-390. PubMed ID: 29193217
[TBL] [Abstract][Full Text] [Related]
47. Subtyping intestinal metaplasia in patients with chronic atrophic gastritis: an interobserver variability study.
Lerch JM; Pai RK; Brown I; Gill AJ; Jain D; Kővári B; Kushima R; Sheahan K; Slavik T; Srivastava A; Lauwers GY; Langner C
Pathology; 2022 Apr; 54(3):262-268. PubMed ID: 35221041
[TBL] [Abstract][Full Text] [Related]
48. Is Gastric Xanthelasma an Alarming Endoscopic Marker for Advanced Atrophic Gastritis and Intestinal Metaplasia?
Köksal AŞ; Suna N; Kalkan İH; Eminler AT; Sakaoğulları ŞZ; Turhan N; Saygılı F; Kuzu UB; Öztaş E; Parlak E
Dig Dis Sci; 2016 Oct; 61(10):2949-2955. PubMed ID: 27250981
[TBL] [Abstract][Full Text] [Related]
49. Long-term sequelae of Helicobacter pylori gastritis.
Kuipers EJ; Uyterlinde AM; Peña AS; Roosendaal R; Pals G; Nelis GF; Festen HP; Meuwissen SG
Lancet; 1995 Jun; 345(8964):1525-8. PubMed ID: 7791437
[TBL] [Abstract][Full Text] [Related]
50. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis.
Wang J; Xu L; Shi R; Huang X; Li SW; Huang Z; Zhang G
Digestion; 2011; 83(4):253-60. PubMed ID: 21282951
[TBL] [Abstract][Full Text] [Related]
51. Pathology of the gastric antrum and body associated with Helicobacter pylori infection in non-ulcerous patients: is the bacterium a promoter of intestinal metaplasia?
Rugge M; Di Mario F; Cassaro M; Baffa R; Farinati F; Rubio J; Ninfo V
Histopathology; 1993 Jan; 22(1):9-15. PubMed ID: 8436350
[TBL] [Abstract][Full Text] [Related]
52. Gastric Intestinal Metaplasia in Children: Natural History and Clinicopathological Correlation.
Mansuri I; Goldsmith JD; Liu E; Bonilla S
J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):332-338. PubMed ID: 37319118
[TBL] [Abstract][Full Text] [Related]
53. Gastric intestinal metaplasia - age, ethnicity and surveillance for gastric cancer.
Simko V; Anand N; Ginter E
Bratisl Lek Listy; 2015; 116(1):3-8. PubMed ID: 25666954
[TBL] [Abstract][Full Text] [Related]
54. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis.
Kim EH; Kang H; Park CH; Choi HS; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Dig Liver Dis; 2015 Aug; 47(8):663-8. PubMed ID: 26077884
[TBL] [Abstract][Full Text] [Related]
55. Helicobacter pylori infection, mucosal atrophy and intestinal metaplasia in Asian populations: a comparative study in age-, gender- and endoscopic diagnosis-matched subjects.
Matsuhisa TM; Yamada NY; Kato SK; Matsukura NM
Helicobacter; 2003 Feb; 8(1):29-35. PubMed ID: 12603614
[TBL] [Abstract][Full Text] [Related]
56. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
[TBL] [Abstract][Full Text] [Related]
57. Gastric intestinal metaplasia: progress and remaining challenges.
Tong QY; Pang MJ; Hu XH; Huang XZ; Sun JX; Wang XY; Burclaff J; Mills JC; Wang ZN; Miao ZF
J Gastroenterol; 2024 Apr; 59(4):285-301. PubMed ID: 38242996
[TBL] [Abstract][Full Text] [Related]
58. Gastric juice prostaglandins and peptide growth factors as potential markers of chronic atrophic gastritis, intestinal metaplasia and gastric cancer: their potential clinical implications based on this pilot study.
Dias A; Garcia C; Majewski M; Wallner G; McCallum RW; Poplawski C; Sarosiek J
Dig Dis Sci; 2011 Nov; 56(11):3220-5. PubMed ID: 21695403
[TBL] [Abstract][Full Text] [Related]
59. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis.
Sitas F; Smallwood R; Jewell D; Millard PR; Newell DG; Meuwissen SG; Moses S; Zwiers A; Forman D
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):119-23. PubMed ID: 8467246
[TBL] [Abstract][Full Text] [Related]
60. [Histological changes of gastric atrophy and intestinal metaplasia after Helicobacter pylori eradication].
Lee Y; Jeon YC; Koo TY; Cho HS; Byun TJ; Kim TY; Lee HL; Eun CS; Lee OY; Han DS; Sohn JH; Yoon BC
Korean J Gastroenterol; 2007 Nov; 50(5):299-305. PubMed ID: 18159161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
